Name: Boc-azetidine-3-carboxylic acid
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

1-Boc-azetidine-3-carboxylic acid; 1-N-Boc-3-Azetidinecarboxylic acid; 1-(tert-Butoxycarbonyl)azetidine-3-carboxylic Acid; azetidine-1,3-dicarboxylic acid mono-tert-butyl ester

IUPAC Name

1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid

Canonical SMILES

CC(C)(C)OC(=O)N1CC(C1)C(=O)O

InChI

InChI=1S/C9H15NO4/c1-9(2,3)14-8(13)10-4-6(5-10)7(11)12/h6H,4-5H2,1-3H3,(H,11,12)

InChIKey

NCADHSLPNSTDMJ-UHFFFAOYSA-N

Density

1.246±0.06 g/cm3

Melting Point

100.1-101.9°C

Appearance

White to off-white powder

Storage

Store at 2-8 °C

Boiling Point

321.0±35.0 °C at 760 mmHg

Boc-azetidine-3-carboxylic acid, a chemical compound pivotal in organic synthesis and medicinal chemistry, boasts a spectrum of applications. Here are four key applications presented with high perplexity and burstiness:

Peptide Synthesis: Acting as a fundamental building block in peptide and peptidomimetic synthesis, Boc-azetidine-3-carboxylic acid infuses rigidity and conformational constraints into peptide chains, elevating binding affinity and selectivity for target proteins. This unique attribute underpins the creation of innovative therapeutic peptides endowed with heightened stability and efficacy.

Drug Design and Development: Within the realm of medicinal chemistry, Boc-azetidine-3-carboxylic acid spearheads the design and synthesis of novel drug candidates. By integrating this compound into drug molecules, researchers can fine-tune their pharmacokinetic and pharmacodynamic properties, fostering the emergence of drugs with enhanced bioavailability, diminished side effects, and enriched therapeutic profiles.

Organic Synthesis: As a versatile intermediary in the synthesis of complex organic molecules, Boc-azetidine-3-carboxylic acid shines in generating chiral building blocks for asymmetric synthesis—an indispensable technique for crafting enantiopure compounds. This capability holds particular significance in pharmaceutical, agrochemical, and fine chemical synthesis, where stereochemistry governs activity and efficacy, propelling scientific advancements at the molecular level.

Bioconjugation: Embracing bioconjugation strategies, Boc-azetidine-3-carboxylic acid plays a pivotal role in tethering bioactive molecules to carriers or functional groups, amplifying the delivery and targeting precision of therapeutic agents like drugs and imaging probes. This strategic application serves to optimize therapeutic indices and diagnostic accuracy in biomedical contexts, accentuating the potential for innovative biomedical technologies and precision medicine approaches.

1.Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia.

Yoshida M1,2, He P1, Yun CC1,3. PLoS One. 2016 Apr 28;11(4):e0154527. doi: 10.1371/journal.pone.0154527.

Lysophosphatidic acid (LPA) acts on LPA2 receptor to mediate multiple pathological effects that are associated with tumorigenesis. The absence of LPA2 attenuates tumor progression in rodent models of colorectal cancer, but whether overexpression of LPA2 alone can lead to malignant transformation in the intestinal tract has not been studied. In this study, we expressed human LPA2 in intestinal epithelial cells (IECs) under control of the villin promoter. Less than 4% of F1-generation mice had germline transmission of transgenic (TG) human LPA2; as such only 3 F1 mice out of 72 genotyped had TG expression. These TG mice appeared anemic with hematochezia and died shortly after birth. TG mice were smaller in size compared with the wild type mouse of the same age and sex. Morphological analysis showed that TG LPA2 colon had hyper-proliferation of IECs resulting in increased colonic crypt depth. Surprisingly, TG small intestine had villus blunting and decreased IEC proliferation and dysplasia.

2.Sensitivity of HIV rapid tests compared to fourth generation enzyme immunoassays or HIV RNA tests - a systematic review and meta-analysis.

Tan WS1, Chow EP, Fairley CK, Chen MY, Bradshaw CS, Read TR. AIDS. 2016 Apr 27. [Epub ahead of print]

OBJECTIVE: Determine the sensitivity of rapid HIV tests (RT) compared to fourth generation enzyme immunoassays (EIA) or nucleic acid amplification tests (NAAT) in clinical settings.

3.Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.

Goswami RS1, Luthra R2, Singh RR1, Patel KP1, Routbort MJ1, Aldape KD3, Yao H4, Dang HD1, Barkoh BA1, Manekia J1, Medeiros LJ1, Roy-Chowdhuri S3, Stewart J3, Broaddus RR3, Chen H3. Am J Clin Pathol. 2016 Feb;145(2):222-237. Epub 2016 Feb 12.

OBJECTIVES: Clinical laboratories are rapidly implementing next-generation sequencing (NGS) tests for mutation analysis, but there are few guidelines regarding sample quality for successful results.

4.MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID.

Cheung AY1, Yonekawa Y, Balaraman S, Thomas BJ, Xi AM, Folberg R, Amin M, Miller KT, Faia LJ. Retin Cases Brief Rep. 2016 Apr 27. [Epub ahead of print]

PURPOSE: To provide correlative clinical-multimodal imaging-histopathologic findings of isolated prostatic choroidal metastasis.